Rational and Rapid Design for Precise Immune Cell Interactions
Move from empirical trial and error to rational design of cell–cell interactions. StimulusBio’s technology is built to help immunologists intentionally shape activation, phenotype, and function in ways that translate into scalable cell products.
Tune signaling architecture
without genetic
modification
Design immune activation using mechanistic insight, not fixed formulations
Drive cell fate
through immune
synapse control
Replace Default Activation With Intentional Design
Immune activation is not a binary switch. Immune cells integrate signals through a spatially organized immune synapse, where both signal composition and spatial dynamics shape downstream phenotype and function.
StimulusBio focuses on intentional cell communication. Signal presentation is treated as a controllable design variable that creates the flexibility to more closely mimic the immune synapse. Scientists can now tailor activation to be explicit, testable, and aligned with the end goal of translation.
Design Immune Interactions Using Mechanistic Insight
StimulusBio’s proprietary technology (sbPCI™) is a programmable cellular interface developed to enable rational, library-based design of immune signaling. In contrast to activation systems that are rigid both in their physical base and their fixed formulations, sbPCI is a highly tunable system that allows signaling architecture to be designed around the biology of interest.
sbPCI provides precise control over the formulation and presentation of signals:
- Identity – which activating, co‑stimulatory, or cytokine cues are presented
- Density and ratio – how much of each cue is available at the interface
- Spatial organization – how cues are distributed and co‑localized
- Context – how multiple signals are integrated simultaneously
By making these parameters explicit, teams move from observational optimization to hypothesis‑driven, mechanistic exploration of immune activation.
Iterate Quickly &
Reduce Dependence on
Genetic Modification
Engineered APCs or feeder cells rely on genetic engineering approaches that impose long design–build cycles. Instead, the surface membrane-bound sbPCI architecture supports high-throughput screening of formulations. By reducing iteration from months to weeks, mechanistic understanding is both deeper and faster while also preserving flexibility as programs move from discovery into process development.
Translate Early Insight Into Scalable Cell Products
sbPCI was designed not only to generate insight, but to carry that insight forward. The same signaling principles explored during discovery can be configured into bead‑free, biocompatible formats intended to reduce workflow complexity and support manufacturing translation.
Teams can avoid the common reset between “what worked in discovery” and “what is manufacturable,” reducing downstream re‑optimization and risk.
Apply Rational Design Across
Immune Cell Applications
StimulusBio’s platform has been used to explore how activation method functions as a primary design lever, not a fixed reagent choice.
- Immune cell activation and expansion directly from PBMCs
- Preferential expansion of therapeutically relevant subsets
- Phenotype shaping linked to early activation design
- Improved workflows in standard processes and equipment (i.e. Grex)
Improved Activation as a Driver to Clinical Utility
We are using precise immune signaling to accelerate the transition from design into clinical cell therapy workflows. Our sbPCI programs include:
CellPilot™ activation reagents
Bead‑free reagents that deliver defined activation cues to support reproducible T cell activation and expansion.CellPilot™ Custom
Program‑specific configuration service that allows signal composition, density, and timing to be tuned specifically to cells or applications of interest.Improved quality assays
Direct linkage between signal presentation and functional outcomes enables more informative assays to assess cell state, consistency, and fitness across development stages.Therapeutic pipeline
Systematic exploration of how defined signaling parameters shape cell function, informing the development of differentiated, product‑relevant cell therapies.